




PHARMACEUTICAL 2018

ImmunoGen Inc.
Rank 271 of 342

immu·gen





PHARMACEUTICAL 2018

ImmunoGen Inc.
Rank 271 of 342



The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 37% points. The greatest weakness of ImmunoGen Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 87% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	276,341
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,770
Liabilities, Non-Current	4,236
Other Assets	3,797
Other Compr. Net Income	0
Other Expenses	40,416
Other Liabilities	252,565
Other Net Income	2,607
Other Revenues	115,447
Property and Equipment	14,538
Research and Development	139,739
Selling, General and Administrative Expense	33,911

Output Variable	Value in 1000 USD
Assets	294,676
Liabilities	312,571
Expenses	214,066
Revenues	115,447
Stockholders Equity	-17,895
Net Income	-96,012
Comprehensive Net Income	-96,012
Economic Capital Ratio	-42%